Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07333352Phase 2Recruiting

PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months

Role: lead

NCT06675032Phase 1Active Not Recruiting

Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years

Role: lead

NCT06678620Phase 2Active Not Recruiting

Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine

Role: lead

NCT06678607Phase 1Completed

Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older

Role: lead

All 4 trials loaded